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Abstract
Background: Chronic antibody-mediated rejection is a major issue that affects long-term renal allograft survival.
Since follicular helper T (Tfh) cells promote the development of antigen-specific B cells in alloimmune responses,
we investigated the potential roles of Tfh cells, B cells and their alloimmune-regulating molecules in the pathogenesis
of chronic renal allograft rejection in this study.
Methods: The frequency of Tfh, B cells and the levels of their alloimmune-regulating molecules including chemokine
receptor type 5 (CXCR5), inducible T cell co-stimulator (ICOS), programmed death-1 (PD-1), ICOSL, PDL-1 and
interleukin-21 (IL-21), of peripheral blood were comparatively measured in 42 primary renal allograft recipients
within 1–3 years after transplantation. Among them, 24 patients had definite chronic rejection, while other 18
patients had normal renal function.
Results: Tfh-cell ratio was significantly increased with PD-1 down-regulation in the patients with chronic renal
allograft rejection, while B cells and the alloimmune-regulating molecules studied did not show any appreciable
change in parallel.
Conclusions: The patients with chronic renal allograft rejection have a characteristic increase in circulating Tfh
cells with a decrease in PD-1 expression. These pathological changes may be a therapeutic target for the treatment of
chronic renal allograft rejection and can be useful as a clinical index for monitoring conditions of renal transplant.
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Background
Renal transplantation remains an effective treatment for
end-stage renal dysfunction [1], facilitating a return to
normal health and prolonging life. However, antibody-
mediated rejection is a major issue that affects long-term
renal allograft survival. Despite the rapid development of
new immunosuppressive drugs for attenuating acute re-
jection, improving the long-term survival of grafts is still a
challenge mainly because of chronic allograft rejection.
The features of chronic renal allograft rejection are hyper-
tension, proteinuria, progressive deterioration of graft
function, peritubular capillary C4d deposition, presence of
donor-specific antibodies (DSA) and morphological
changes with transplant vasculopathy, glomerulopathy,
fibrosis and lymphocyte infiltration. However, the causes
leading to chronic rejection are complex and not well
understood yet [2].
Allograft rejection is characterized by an increase in
activated CD4+ T-lymphocytes, especially regulatory and
cytotoxic T cells, leading to an imbalance of immune re-
sponses in the transplant recipients [3, 4]. Functionally,
CD4+ T helper cells that interact with antigen-specific B
cells are required for the production of alloantibodies
[5]. Among them, Tfh cells, a recently defined subset of
CD4+ T cells, play a particular role in mediating B cell-
driven allogeneic responses. Tfh cells can migrate into
germinal centers and promote B-cell activation and
differentiation into immunoglobulin-producing plasma-
blasts or plasma cells [5]. They can express PD-1,
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lymphoma 6 (Bcl-6) [6, 7], thereby displaying their regu-
latory functions.
Circulating Tfh cells, peripheral counterparts of
conventional Tfh cells, express PD-1, CXCR5, ICOS
and IL-21, but not Bcl-6 [5–7]. They play an import-
ant role in human humoral immunity through these
functional molecules. Their abnormal activities are
critically involved in the onset of several human dis-
eases such as autoimmune disorders, cancer and in-
fective diseases [7–10]. Therefore, an alteration in
circulating Tfh cells may be correlated with disease
conditions and might be used as a biomarker of cer-
tain diseases [11–13]. Moreover, recent clinical studies
have shown that peripheral Tfh cells in the kidney
transplant recipients with acute rejection can regulate
B-cell alloreactivity and the number of these Tfh cells
alters the immunization status and DSA levels [14].
However, their function and relevance to chronic
renal allograft rejection are not known yet.
This study was conducted to explore the potential
association between circulating Tfh cells and chronic
rejection in kidney transplant recipients. The outcome
results may provide a useful hint for clinical predic-
tion of renal status after transplantation and for a
potential new therapy for chronic allograft rejection.
Methods
This study was approved by the Institutional Ethics
Committee of Third Affiliated Hospital of Soochow
University, Jiangsu Province, China. Written-informed
consent was obtained from all participants of the study.
Subjects
The patients with primary renal transplantation for 1–3
years were enrolled from October 2013 to December
2014. Totally 42 recipients were studied in this work, in-
cluding 24 patients with chronic rejection (CR group)
and 18 patients with normal renal function as the nor-
mal control (NC group). All of them received the treat-
ment with cyclosporine A, methylprednisolone and
mycophenolate mofetil or azathioprine after the renal
transplantation. The diagnosis for chronic allograft rejec-
tion was confirmed by renal biopsy, biochemical mea-
surements and immunological assays, including DSA as
described in other studies [15–18]. In specific,the diag-
nostic criteria included 1) clinical evidence of slowly de-
teriorating graft function; 2) biopsy evidence and diffuse
deposition of C4d; and 3) the presence of circulating
DSA at the time of biopsy. Their peripheral blood sam-
ples were collected in a standard way by the clinical
laboratory of the hospital. All the subjects had no infect-
ive disease when sampling blood.
Surface staining and flow cytometry analysis
The whole blood was subjected to flow cytometry detec-
tion by a BD bioscience FACSCantoII cytometer with
FACSDiva software for measuring the frequency of circu-
lating Tfh cells and B cells as well as the expression of
their surface markers. The following conjugated monoclo-
nal antibodies were used to stain the cells: CD4-FITC,
CXCR5-APC, ICOS-PE, PD-1-PE, CD19-PE-Cy5.5,
ICOSL-PE and PDL-1-APC. The cells were incubated
with the antibodies for 30 min at room temperature in the
dark. Totally 50,000 lymphocytes were acquired in each
sample. Data were analyzed using Flow Jo software 7.6.1.
Enzyme-linked immunosorbent assay (ELISA)
The levels of serum IL-21 were quantified by using the
human IL-21 ELISA kit (eBioscience) according to the
manufacturer’s instructions. The concentration in each
individual sample was calculated according to the standard
curve.
Statistical analyses
All experimental data were analyzed by Graph Prism
version 5.0. The results were expressed as mean ± SD
and subjected to t test for statistical comparisons be-
tween the NC and CR groups. If a p-value was found to




The general information of the renal transplant recipi-
ents was summarized in Table 1. Gender and age were
similar between CR and NC groups. The mean serum
creatinine (sCr) and blood urea nitrogen (BUN) were al-
most three-fold higher in the CR patients than those of
NC group (p < 0.001).
Increased circulating Tfh cells in the CR patients
To determine if chronic rejection was associated with an
alteration in circulating Tfh cells in the renal transplant-
ation recipients, we first evaluated the frequency of CD4
+ CXCR5+ Tfh cells through flow cytometry. As shown
in Fig. 1, the percentage of CD4 + CXCR5+ Tfh cells
among total CD4+ T cells was significantly increased in
the CR group as compared to that of the NC group
(35.3 ± 8.5 % vs.19.0 ± 5.0, P < 0.001).
Table 1 General information of the renal transplant patients
Group Gender Age SCr BUN
(male/female) (μmol/L) (mmol/L)
NC 16/8 42 ± 7 95.4 ± 18.6 5.3 ± 1.6
CR 12/6 49 ± 9 277.0 ± 124.3*** 15.2 ± 7.8***
NC, normal control; CR, chronic rejection. P < 0.001 *** vs. NC
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Differential changes in PD-1, CXCR5, ICOS, and IL-21 of Tfh
cells in the CR patients
We further detected the changes of PD-1, CXCR5 and
ICOS in the high frequency of Tfh cells and found that
PD-1 was significantly down-regulated in these Tfh cells
(Fig. 2a). In sharp contrast, there were no significant
changes in CXCR5 and ICOS in the CR group as com-
pared to the NC group (Fig. 2b and c).
IL-21 is a biological hallmark of Tfh cells because this
immune cytokine is produced by Tfh cells and is in-
volved in mediating Tfh-B-cell interaction [6]. There-
fore, we further measured the concentration of IL-21 in
the serum of the CR patients (Fig. 3). Similarly as the
changes in CXCR5 and ICOS, serum IL-21 did not
show any significant change in the CR patients as com-
pared to that of the control group (406.9 ± 123.9 pg/ml
vs. 449.1 ± 101.7 pg/ml, P > 0.05).
No changes in circulating B cells, PDL-1 and ICOSL in the
CR patients
Since B cells are key players in the graft rejection
[19], we further determined the frequency of total B
cells and compared their change with that of Tfh
cells. The ratio of B lymphocytes was not significantly
different between CR and NC groups (Fig. 4), unlike
Tfh cells. Because PDL-1-expressing B cells interact
with PD-1+ Tfh cells to regulate the maturation and
survival of B cells [20], we next detected the expres-
sion of PDL-1 in B cells. Unlike the change in the
PD-1 of Tfh cells, PDL-1 did not decrease in B cells
at all in the CR group (Fig. 5a). Also, ICOSL had no
significant change in the CR patients (Fig. 5b).
All these results suggest that the increase in circulating
Tfh cells with PD-1 down-regulation is a specific and
characteristic change in the CR patients.
Discussion
We have made a novel finding in this work, i.e., a major
increase in circulating Tfh cells with a significant de-
crease in PD-1 in the patients with chronic renal allo-
graft rejection. In sharp contrast, B cells and the
alloimmune-regulating molecules such as CXCR5, ICOS,
ICOSL, PDL-1 and IL-21 did not show any appreciable
change in parallel.
Tfh cells display multiple features for their helper func-
tions in secondary lymphoid organs or tissues with inflam-
mation [21]. They migrate into B cell follicles of germinal
centers [22] and thereby help B cells generate antibodies
for humoral immunity [3, 6, 23]. In fact, Tfh cells, as an
immune regulator, are critically involved in the patho-
logical processes of many immune diseases [8]. In renal
allograft rejection, the germinal center reactions are
dependent on Tfh, while B cells are indispensable for the
immune attack to the newly transplanted kidney [24].
Tfh cells express PD-1 [6], while B cells produce PDL-1,
an endogenous ligand of PD-1 [19]. The PD-1/PDL-1 sig-
naling has been shown to play an important role in regu-
lating immune functions and affecting the activation of
regulatory T cells, cytotoxic T cells and Dendritic cells
[25]. Such signaling also influences the generation and dif-
ferentiation of Tfh and B cells themselves [26]. Recent evi-
dence suggests that blocking the PD-1 signaling induces
an up-regulation of Tfh generation and differentiation,
which may directly lead to autoimmune encephalomyelitis
[27]. In contrast, stimulating this pathway can prolong the
survival of the patients after cardiac allograft transplant-
ation [28]. More recently, PD-1 ligands are found to pro-
tect the kidneys from ischemia reperfusion injury [29]. In
fact, PDL-1, the endogenous ligand of PD-1, has been
demonstrated as a required factor for peripheral trans-
plantation tolerance and protection aganist chronic allo-
graft rejection [30].
Fig. 1 Frequency of Tfh cells in the patients with renal allograft. a, representative contour plots of the ratio of Tfh cells in the NC and CR groups, b, mean
values of the frequency of Tfh cells in the two groups. ***, P < 0.001. Note a significant increase in Tfh cells in the CR group compared to that
of the control group
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Taken together, PD-1 signaling is a key regulator for
attenuating the Tfh cells and down-regulating the over-
reaction of humoral immunity against the transplanted
kidneys. Therefore, the novel finding of the present
study strongly suggests that the deficiency of PD-1 ex-
pression causes the increase in Tfh cells, thereby leading
to an overreaction of humoral immunity against the al-
lergenic organ, which may be a major reason for chronic
allograft rejection.
Tfh and B cells also express many other immune-
regulating molecules such as CXCR5, ICOS, ICOSL, and
IL-21 [6, 19, 26]. All these molecules are actively
involved in the regulation of immune function [26]. For
example, an increase in the expression of CXCR5 can
enable Tfh cells to migrate into germinal centers [21].
On the other hand, ICOS, another surface receptor like
PD-1, also mediate the generation, development and
function of Tfh cells by activating ICOS/ICOSL signaling
[31, 32]. Moreover, IL-21,a pro-inflammatory cytokine
secreted by Tfh cells,has an important role in Tfh cell
differentiation, B cell proliferation [33], and the expres-
sion of PD-1 [34] and CXCR5 [26]. However, all of these
immune regulators did not shown any change in the
patients with chronic allograft rejection. We are there-
fore confident that the deficient PD-1 expression with
increased circulating Tfh cells is a specific and character-
istic change in chronic allograft rejection.
In the lymph nodes, CD4+ CXCR5+ Tfh cells are
more effective in helping B cells than their peripheral
counterparts [7]. Humoral response in the lymph nodes
can be suppressed by anti-CD40 mAb via regulating Tfh
cells [23]. In the transplanted kidneys with acute rejec-
tion, infiltrated Tfh cells have been found to participate
in the antibody-mediated rejection [14]. However, little
Fig. 3 The level of serum IL-21 in renal allograft patients. Note that
there was no statistic difference in the IL-21 level between the CR and
NC groups
Fig. 4 The frequency of B cells. Note that there was no significant
difference between two groups
Fig. 2 Comparative changes in PD-1, CXCR5 and ICOS expression on
Tfh-cell surfaces. a,PD-1. b, CXCR5. c, ICOS. * P < 0.05. Note a significant
decrease in PD-1 expression with no appreciable changes in CXCR5 and
ICOS expression in the CR patients as compared to the NC group
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is known about the role of these special Tfh cells in the
transplanted kidneys with chronic rejection. We specu-
late that the increase in circulating Tfh cells with a de-
crease in PD-1 expression might, at least partially,
contributes to the genesis of the renal chronic rejection
by migrating and infiltrating into germinal centers of
renal allografts and lymphoid organs. We will further
clarify this issue in our future work.
In addition, pre-existent DSA storing before renal
transplantation and de-novo DSA developing after renal
transplantation are associated with antibody-mediated
rejection and allograft failure [35]. However, recent stud-
ies have shown that despite the numbers of circulating
Tfh cells were higher in the patients with pre-existent
DSA than those without pre-existent DSA, the levels of
circulating Tfh cells were not different among the pa-
tients with or without de-novo DSA [35, 36]. Therefore,
the relationship between the frequency of circulating Tfh
cells and the level of DSA in renal allograft rejection is
not clear yet and needs more investigations.
Conclusions
Our first data show that decreased PD-1 expression may
contribute to the increase in circulating Tfh cells in the
patients with chronic renal allograft rejection. This
finding provides a potential hint for a new target for the
treatment of chronic rejection. Moreover, a dynamic
change in the expression of PD-1 and the number of cir-
culating Tfh cells may be used as an index for monitoring
chronic allograft rejection after kidney transplantation as.
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